Literature DB >> 22584796

Gluco- and mineralocorticoid biological effects of a 7-day treatment with low doses of hydrocortisone and fludrocortisone in septic shock.

Bruno Laviolle1, Djillali Annane, Claire Fougerou, Eric Bellissant.   

Abstract

PURPOSE: The benefits of low-dose steroids in septic shock remain controversial. We investigated if these low doses were able to induce their expected hormonal effects by analyzing the biological modifications observed during the study, which first demonstrated the survival benefit of low-dose steroids.
METHODS: This was a multicenter, placebo-controlled, randomized, double-blind study in which 299 septic shock patients received a 7-day treatment with a combination of hydrocortisone (50 mg intravenously four times daily) and fludrocortisone (50 μg orally once daily) or matching placebos. Gluco- and mineralocorticoid biological effects observed during the 7 days of treatment were compared between groups.
RESULTS: Steroids significantly decreased eosinophil counts from day 2 to day 7. Steroids significantly increased plasma glucose from day 2 (compared with placebos: +0.8 mmol/l) to day 7 (+1.8 mmol/l) and cholesterol from day 3 (+0.54 mmol/l) to day 7 (+0.39 mmol/l). Steroids significantly increased plasma sodium from day 3 (+2 mmol/l) to day 7 (+5 mmol/l) and significantly decreased plasma potassium on day 7 (-0.2 mmol/l). Steroids significantly decreased urinary sodium/potassium ratio from day 2 (-47 %) to day 7 (-57 %) and sodium fractional excretion from day 3 (-25 %) to day 7 (-66 %). Steroids significantly increased urine output on day 4 and 5 and osmolar clearance from day 4 to day 7, and decreased free-water clearance from day 4 to day 7, this effect being significant on day 4 and 6.
CONCLUSIONS: In septic shock, low-dose steroids induced both gluco- and mineralocorticoid biological effects and seemed to improve renal function. Most of these effects appeared after 2-3 days of treatment and lasted at least until the end of treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22584796     DOI: 10.1007/s00134-012-2585-1

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  35 in total

1.  Relative eosinophilia and functional adrenal insufficiency in critically ill patients.

Authors:  A Beishuizen; I Vermes; B S Hylkema; C Haanen
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

Review 2.  Corticosteroid insufficiency in acutely ill patients.

Authors:  Mark S Cooper; Paul M Stewart
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

Review 3.  Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis.

Authors:  Djillali Annane; Eric Bellissant; Pierre Edouard Bollaert; Josef Briegel; Didier Keh; Yizhak Kupfer
Journal:  BMJ       Date:  2004-08-02

4.  S-Methylisothiourea sulfate improves renal, but not hepatic dysfunction in canine endotoxic shock model.

Authors:  C Mitaka; Y Hirata; Y Masaki; T Takei; K Yokoyama; T Imai
Journal:  Intensive Care Med       Date:  2000-01       Impact factor: 17.440

5.  Renal hemodynamics and water excretion in Addison's disease.

Authors:  A P Quintanilla; C Delgado-Butron; J Zeballos
Journal:  Metabolism       Date:  1976-04       Impact factor: 8.694

6.  Biological and hemodynamic effects of low doses of fludrocortisone and hydrocortisone, alone or in combination, in healthy volunteers with hypoaldosteronism.

Authors:  B Laviolle; P Le Maguet; M-C Verdier; C Massart; E Donal; F Lainé; A Lavenu; D Pape; E Bellissant
Journal:  Clin Pharmacol Ther       Date:  2010-07-14       Impact factor: 6.875

Review 7.  Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.

Authors:  Djillali Annane; Eric Bellissant; Pierre-Edouard Bollaert; Josef Briegel; Marco Confalonieri; Raffaele De Gaudio; Didier Keh; Yizhak Kupfer; Michael Oppert; G Umberto Meduri
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

8.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

9.  Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial.

Authors:  Djillali Annane; Alain Cariou; Virginie Maxime; Elie Azoulay; Gilles D'honneur; Jean François Timsit; Yves Cohen; Michel Wolf; Muriel Fartoukh; Christophe Adrie; Charles Santré; Pierre Edouard Bollaert; Armelle Mathonet; Roland Amathieu; Alexis Tabah; Christophe Clec'h; Julien Mayaux; Julie Lejeune; Sylvie Chevret
Journal:  JAMA       Date:  2010-01-27       Impact factor: 56.272

Review 10.  Glucocorticoids in sepsis: dissecting facts from fiction.

Authors:  Paul E Marik
Journal:  Crit Care       Date:  2011-05-06       Impact factor: 9.097

View more
  10 in total

1.  Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.

Authors:  Noureddine Hamitouche; Emmanuelle Comets; Mégane Ribot; Jean-Claude Alvarez; Eric Bellissant; Bruno Laviolle
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

2.  Protective effects of glucocorticoid on liver injury in a rat sepsis model.

Authors:  Xiaoli Li; Meifeng Li; Luyi Liu; Xinghan Tian; Yafeng Liang
Journal:  Exp Ther Med       Date:  2019-08-16       Impact factor: 2.447

3.  Hydrocortisone with fludrocortisone for septic shock: a systematic review and meta-analysis.

Authors:  Ryo Yamamoto; Isao Nahara; Mitsunobu Toyosaki; Tatsuma Fukuda; Yoshiki Masuda; Seitaro Fujishima
Journal:  Acute Med Surg       Date:  2020-09-01

4.  A high leukocyte count and administration of hydrocortisone hamper PCR-based diagnostics for bloodstream infections.

Authors:  Andreas E Posch; Dorothea Orth-Höller; Silke Huber; Johannes Weinberger; Matthias Pilecky; Ingo Lorenz; Anita Schildberger; Viktoria Weber; Stefan Fuchs; Wilfried Posch; Ludwig Knabl; Reinhard Würzner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-02-05       Impact factor: 3.267

Review 5.  Immune Effects of Corticosteroids in Sepsis.

Authors:  Nicholas Heming; Sivanthiny Sivanandamoorthy; Paris Meng; Rania Bounab; Djillali Annane
Journal:  Front Immunol       Date:  2018-07-30       Impact factor: 7.561

Review 6.  The role of eosinophils in sepsis and acute respiratory distress syndrome: a scoping review.

Authors:  Zainab Al Duhailib; Malik Farooqi; Joshua Piticaru; Waleed Alhazzani; Parameswaran Nair
Journal:  Can J Anaesth       Date:  2021-01-25       Impact factor: 6.713

7.  Year in review in Intensive Care Medicine 2012: I. Neurology and neurointensive care, epidemiology and nephrology, biomarkers and inflammation, nutrition, experimentals.

Authors:  Massimo Antonelli; Marc Bonten; Maurizio Cecconi; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Salvatore M Maggiore; Jordi Mancebo; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2012-12-18       Impact factor: 17.440

Review 8.  The Role of ACTH and Corticosteroids for Sepsis and Septic Shock: An Update.

Authors:  Djillali Annane
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-20       Impact factor: 5.555

9.  Effect of hydrocortisone on the 28-day mortality of patients with septic acute kidney injury.

Authors:  Pan Ying; Chenguang Yang; Xianlong Wu; Qiqi Cai; Wenwei Xin
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

Review 10.  General Adaptation in Critical Illness: Glucocorticoid Receptor-alpha Master Regulator of Homeostatic Corrections.

Authors:  Gianfranco Umberto Meduri; George P Chrousos
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-22       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.